Third Rock leads $65M A round for Celsius

Celsius Therapeutics (Cambridge, Mass.) launched with a $65 million series A round led by Third Rock Ventures. Also participating were GV, Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and undisclosed other investors.

Celsius aims to discover and develop precision therapeutics for autoimmune diseases and cancer. Its technology applies single-cell genomic sequencing to defined patient population samples and uses computational machine-learning algorithms along with big data sets to distinguish the specific cells that play a key role in disease and identify which genes trigger their malfunction (see BioCentury, May 15)...